Regulus Appoints Mohammad Ahmadian, Ph.D., as Vice President, Chemistry and Pharmaceutical Development



SAN DIEGO, Dec 3 2021 / PRNewswire / – Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative drugs targeting microRNAs (the “Company” or “Regulus”), today announced the appointment of Mohamed Ahmadien, Ph.D., as Vice President, Chemistry and Pharmaceutical Development. In his role, Dr Ahmadian will help manage the research and development of the Company’s drug candidates, including RGLS8429, which is being developed for patients with autosomal dominant polycystic kidney disease (ADPKD), and will add significant expertise. to the existing scientific talent of Regulus. .

Logo Regulus Therapeutics Inc.

“We are delighted to welcome Moh to the Regulus team,” said Denis drygin, Scientific Director of Regulus. “Moh brings over 20 years of drug discovery and development experience to the company and we believe his specific experience working with oligonucleotides makes him uniquely qualified for the role. We look forward to leveraging his expertise. as we continue to make progress in the development of RGLS8429, as well as our research programs.

Prior to joining Regulus, Dr Ahmadian was Vice President and Resident Director of Kinovate Life Sciences, Inc., where in addition to being the Technical Lead, he was responsible for operations including production oversight, control quality, quality assurance and procurement. chain. Prior to Kinovate, Dr Ahmadian worked at Nitto Denko Technical Corporation where he managed various projects relating to the design, manufacture and development of therapeutic oligonucleotide processes. Previously, he worked for various life science companies as a research chemist and RNA chemistry project manager. Dr Ahmadian holds a doctorate. in medicinal chemistry of Purdue University and a M.Sc. in organic chemistry from Bullet State University.

NASDAQ Listing Rule 5635 (c) (4) Incentive Grant

As part of his hiring on December 1, 2021, Dr. Ahmadian received an option to purchase 200,000 common shares of Regulus, with an exercise price of $ 0.36 per share, which is the fair market value on the grant date. The option has a term of 10 years and vest over a period of four years, with 25% vesting on December 1, 2022, which is one year after the grant date and the remaining 75% vest on a pro rata basis over the following thirty-six months, subject to continued service by Dr. Ahmadian until each vesting date, and subject to of the terms and conditions of the Regulus incentive plan and notice of grant of stock options and agreement thereunder.

About Regulus

Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative drugs targeting microRNAs. Regulus has leveraged its expertise in oligonucleotide drug discovery and development to develop a pipeline complemented by a rich heritage of intellectual property in the field of microRNAs. Regulus is headquartered in San Diego, CALIFORNIA.

Forward-looking statements

Statements contained in this presentation regarding matters which are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with employees of the Company and their potential impact on our programs. research and development. Since these statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes”, “anticipates”, “plans”, “expects”, “intends”, “will”, “the goal”, “the potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Regulus’ current expectations and involve assumptions which may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements due to various risks and uncertainties, which include, but are not limited to, risks associated with the process of drug discovery, development and commercialization. safe and

effective for use as human therapy and as part of building a business around these drugs, and the risk that additional toxicological data may be negative. Additionally, while Regulus expects the COVID-19 pandemic to adversely affect its business operations and financial results, the extent of the impact on Regulus’ ability to meet its preclinical and clinical development goals and the value and market of its common stock, is dependent on future developments which are very uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, distancing requirements social and business closure in the United States and other countries; and the effectiveness of global measures to contain and treat the disease. These and other risks are described in more detail in filings by Regulus with the Securities and Exchange Commission, including under the heading “Risk Factors” of Regulus’ latest Quarterly Report on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus does not undertake to update these statements to reflect events that occur or circumstances that exist after the date on which they were made.



View original content to download multimedia:

SOURCE Regulus Therapeutics Inc.



Comments are closed.